The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Safety and efficacy of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis
Harinder Gill, MBBS, PDipID, MD, MRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China, shares some insights into the P1101MF study (NCT04988815), which is evaluating the safety and efficacy of ropeginterferon alfa-2b in patients with pre-fibrotic myelofibrosis (MF). Dr Gill comments on the rate of hematologic response observed and further highlights the promise of this agent for the treatment of MF. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
